No connection

Search Results

EHC

BULLISH
$101.98 Live
Encompass Health Corporation · NYSE
Target $142.73 (+40.0%)
$92.77 52W Range $127.99
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$10.14B
P/E
18.37
ROE
24.8%
Profit margin
9.5%
Debt/Equity
0.83
Dividend yield
0.75%

AI Analysis

AI-powered fundamental assessment

Confidence
85%
EHC presents a stable financial profile with a Piotroski F-Score of 4/9 and a significant valuation gap between its defensive Graham Number ($55.18) and growth-based Intrinsic Value ($163.72). The company exhibits exceptional operational efficiency with an ROE of 24.82% and a highly attractive PEG ratio of 0.41, suggesting the stock is undervalued relative to its earnings growth. While insider sentiment is bearish and technical trends are currently weak, the long-term fundamental trajectory is supported by a 25-quarter track record of consistent earnings beats. The current price of $101.98 represents a reasonable entry point given the analyst target of $142.73.

Key Strengths

Exceptional earnings track record with consistent beats over 25 quarters
Very low PEG ratio (0.41) indicating strong growth at a reasonable price
High Return on Equity (24.82%) demonstrating efficient capital use
Strong earnings growth (21.20% YoY) outpacing revenue growth
Conservative dividend payout ratio (12.97%) allowing for significant future increases

Key Risks

Bearish insider activity with significant selling by the CEO and other officers
Weak technical trend (0/100) indicating short-term price momentum is negative
Tight liquidity with a current ratio of 1.08
Significant gap between current price and defensive Graham Number
Exposure to healthcare regulatory risks as noted in 10-K Item 1A
AI Fair Value Estimate
Based on comprehensive analysis
$135.0
+32.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
74
Strong
Value
82
Future
92
Past
95
Health
55
Dividend
45
AI Verdict
Strong Fundamental Value with Short-term Technical Headwinds
Key drivers: Earnings consistency, Low PEG ratio, High ROE, Insider selling
Confidence
90%
Value
82/100

P/E 18.37, PEG 0.41, Graham $55.18

Positives
  • PEG ratio of 0.41 is deeply undervalued
  • Forward P/E (15.74) is lower than current P/E
Watchpoints
  • Trades at a premium to the Graham Number ($55.18)
Future
92/100

Ref Growth rates and Analyst Targets

Positives
  • 21.2% Earnings growth
  • Strong analyst target price of $142.73
Watchpoints
  • Revenue growth (9.9%) is slower than earnings growth
Past
95/100

Ref Historical earnings track record

Positives
  • Consistent EPS beats over 25 quarters
  • Steady 5-year price appreciation (+54.8%)
Watchpoints
No urgent risks highlighted.
Health
55/100

Ref Piotroski F-Score 4/9

Positives
  • Manageable Debt/Equity (0.83)
Watchpoints
  • Piotroski F-Score of 4/9 is only 'Stable'
  • Current ratio (1.08) is lean
Dividend
45/100

Ref Yield 0.75%, Payout 12.97%

Positives
  • Very low payout ratio (12.97%)
Watchpoints
  • Low dividend yield (0.75%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$101.98
Analyst Target
$142.73
Upside/Downside
+40.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for EHC and closest competitors.

Updated 2026-04-24
EHC
Encompass Health Corporation
Primary
5Y
+54.8%
3Y
+64.6%
1Y
+1.2%
6M
-18.8%
1M
+3.4%
1W
-4.2%
TEM
Tempus AI, Inc.
Peer
5Y
+41.1%
3Y
+41.1%
1Y
+38.6%
6M
-38.6%
1M
+20.9%
1W
+23.5%
DVA
DaVita Inc.
Peer
5Y
+34.0%
3Y
+73.9%
1Y
+8.8%
6M
+17.5%
1M
-2.1%
1W
+2.7%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-47.0%
3Y
-22.7%
1Y
-10.4%
6M
+26.6%
1M
+0.7%
1W
+0.7%
TEC
Bio-Techne Corporation
Peer
5Y
-41.6%
3Y
-26.4%
1Y
+28.2%
6M
-2.9%
1M
+17.7%
1W
+5.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
18.37
Forward P/E
15.74
PEG Ratio
0.41
P/B Ratio
4.18
P/S Ratio
1.71
EV/Revenue
2.29
EV/EBITDA
9.86
Market Cap
$10.14B

Profitability

Profit margins and return metrics

Profit Margin 9.54%
Operating Margin 18.35%
Gross Margin 43.21%
ROE 24.82%
ROA 9.66%

Growth

Revenue and earnings growth rates

Revenue Growth +9.9%
Earnings Growth +21.2%
Q/Q Revenue Growth +9.94%
Q/Q Earnings Growth +20.8%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.83
Moderate
Current Ratio
1.08
Good
Quick Ratio
0.83
Poor
Cash/Share
$0.73

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$1.5B
Gross Margin
95.8%
Op. Margin
18.3%
Net Margin
9.5%
Total Assets
$7.1B
Liabilities
$3.8B
Equity
$2.4B
Debt/Equity
1.56x
Operating CF
$0.3B
CapEx
$-0.2B
Free Cash Flow
$0.1B
FCF Yield
34%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-30
$N/A
2026-02-05
$1.46
+12.1% surprise
2025-10-29
$1.23
+3.2% surprise
2025-08-04
$1.4
+15.8% surprise

Healthcare Sector Comparison

Comparing EHC against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
P/E Ratio
18.37
This Stock
vs
77.48
Sector Avg
-76.3% (Discount)
Return on Equity (ROE)
24.82%
This Stock
vs
-89.9%
Sector Avg
-127.6% (Below Avg)
Profit Margin
9.54%
This Stock
vs
-16.4%
Sector Avg
-158.2% (Weaker)
Debt to Equity
0.83
This Stock
vs
2.71
Sector Avg
-69.4% (Less Debt)
Revenue Growth
9.9%
This Stock
vs
126.74%
Sector Avg
-92.2% (Slower)
Current Ratio
1.08
This Stock
vs
4.53
Sector Avg
-76.1% (Weaker)

Similar Companies

Peer comparison within the same industry

EHC Encompass Health...
BULLISH
Mkt Cap
$10.1B
P/E
18.4
ROE
24.8%
Price
$101.98
TEM Tempus AI, Inc.
BEARISH
Mkt Cap
$10.2B
P/E
-
ROE
-89.5%
Price
$56.78
 Compare with EHC
DVA DaVita Inc.
NEUTRAL
Mkt Cap
$10.0B
P/E
16.0
ROE
64.8%
Price
$151.85
 Compare with EHC
BIO-B Bio-Rad...
BEARISH
Mkt Cap
$9.8B
P/E
-
ROE
-9.5%
Price
$312.75
 Compare with EHC
TECH Bio-Techne Corporation
NEUTRAL
Mkt Cap
$9.5B
P/E
114.3
ROE
4.0%
Price
$60.58
 Compare with EHC

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

REIDY CHRISTOPHER R
Director
Stock Award
2026-04-16
353 shares · $35,564
CHRISTIE EDWARD M III
Director
Stock Award
2026-04-16
270 shares · $27,710
WILLIAMS TERRANCE
Director
Stock Award
2026-04-15
27 shares
O'CONNOR KEVIN J
Director
Stock Award
2026-04-15
17 shares
HAYES CAIN A.
Director
Stock Award
2026-04-15
1 shares
CARMICHAEL GREGORY D
Director
Stock Award
2026-04-15
27 shares
SCHLICHTING NANCY M
Director
Stock Award
2026-04-15
39 shares
KATZ LESLYE G
Director
Stock Award
2026-04-15
85 shares
HERMAN JOAN E
Director
Stock Award
2026-04-15
85 shares
FAY EDMUND M
Officer and Treasurer
Gift
2026-03-09
3,000 shares
FAY EDMUND M
Officer and Treasurer
Sell
2026-03-09
11,937 shares · $1,277,259
CHARBONNEAU ELISSA JOY
Officer
Stock Award
2026-02-19
10,798 shares
DARBY JOHN PATRICK
General Counsel
Stock Award
2026-02-19
19,874 shares
TUER PATRICK WILLIAM
Chief Operating Officer
Stock Award
2026-02-19
14,044 shares
TARR MARK J
Chief Executive Officer
Stock Award
2026-02-19
113,742 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-07

EHC filed a definitive proxy statement on April 7, 2026, providing shareholders with necessary information to vote at the company's annual meeting.

8-K
8-K
2026-03-10
10-K
10-K
2026-02-26

EHC filed its annual 10-K report on February 26, 2026. The filing includes detailed sections on business operations, risk factors, and management's discussion and analysis of financial condition.

8-K/A
8-K/A
2026-02-20

EHC filed an amendment to a previously submitted Current Report on Form 8-K.

8-K
8-K
2026-02-05

EHC filed an 8-K on February 5, 2026, likely to announce its quarterly or annual financial results.

8-K
8-K
2026-02-02

EHC filed an 8-K on February 2, 2026, likely to announce its financial results for the most recent fiscal period.

8-K
8-K
2025-12-01
10-Q
10-Q
2025-10-31

EHC filed its quarterly 10-Q report on October 31, 2025. While the filing includes a section dedicated to Risk Factors under Item 1A, specific financial highlights and detailed risk disclosures were not provided in the available excerpt.

8-K
8-K
2025-10-29

EHC filed an 8-K on October 29, 2025, likely to announce its third-quarter financial results.

8-K
8-K
2025-09-18
8-K
8-K
2025-09-12
10-Q
10-Q
2025-08-06
8-K
8-K
2025-08-04
8-K
8-K
2025-06-25
8-K
8-K
2025-06-03
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
11 analysts
Barclays
2026-02-06
Maintains
Overweight Overweight
Barclays
2025-10-30
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning EHC from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile